BDBM503416 (5M)-2-[(1S)-1-amino-1,3- dihydrospiro[indene-2,4''-piperidin]-1''- yl]-5-(2,3-dichlorophenyl)-6- methylpyrimidine-4-carboxamide::US11033547, Compound 119::US11033547, Compound 120::US11033547, Compound 121::US11033547, Compound 122::US11033547, Compound 123::US11033547, Compound 124::US11033547, Compound 125::US11033547, Compound 126::US11033547, Compound 127::US11033547, Compound 128::US11033547, Compound 129::US11033547, Compound 130::US11033547, Compound 131::US11696916, Compound 131

SMILES N[C@H]1c2cccnc2OC11CCN(CC1)c1nc(N)c(-c2cccc(Cl)c2Cl)c(n1)C(N)=O

InChI Key InChIKey=WVQZCPJJNYMBDR-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 503416   

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 270nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 17nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 15nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 530nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 1.20E+3nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 330nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 77nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 7.00E+3nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/5/2021
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 77nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Merck Patent

US Patent
LigandPNGBDBM503416(US11033547, Compound 119 | (5M)-2-[(1S)-1-amino-1,...)
Affinity DataIC50: 7.00E+3nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent